Objective To study the relationship between changes of serum TRAb,TGA,TMA levels and the rate of early hypothy-roidism in patients with Graves' disease treated with [3]I. Methods The serum TRAb,TGA,TMA coaceutratious were measured 3 months before treatment and 3,6,12 and 18 months after therapy in 215 Graves' patients with chemiluminescence immunoassay ( CLIA). These patients were divided into cure group and early hypothyioidism group according to the clinical symptoms and laboratory test results. Results After 3 months of treated with[3],the serum TRAb level was significantly increased (P >0.Q5) , TGA,TMA levels in patients were minor difference form before treatment(P0.05). The positive rates of serum TGA, TMA in early hypothyroidism patients were obviously higher than another groups ( P > 0.05 ). Conclusion There is very important clinical significance for the Graves' patients to accept the developmental observation of serum TRAb,TGA and TMA concentrations both before and after [3]I Therapy,which provides a great of positive information for observation therapeutic effects,prognosis judgement and to evaluate the prognosis early hypothyroidism. Thereby, these laboratory items should place priority on Graves' disease.%目的 测定Graves病患者131I治疗前后血清TRAb、TGA、TMA水平,探讨其变化规律及与早发甲减的关系.方法 收集215例经131I治疗的Graves病患者,根据临床症状和实验室检查结果分为治愈组和早发甲减组,应用化学发光免疫分析测定患者治疗前3个月,治疗后3 、6 、12 、18 个月血清TRAb、TGA、TMA 的含量,并进行比较.结果 131I治疗后3个月血清TRAb 含量明显升高(P0.05).治疗后6个月TRAb达最高值并呈下降趋势,TGA、TMA 值明显升高.治疗后12 个月TRAb、TGA、TMA 值明显下降,治疗后18个月各项指标均接近正常.治愈组患者TRAb阳性率显著地低于其他组(P<0.05),早发甲减组患者TGA、TMA阳性率显著地高于其他组(P<0.05).结论 动态监测Graves病患者131I治疗前后血清TRAb、TGA、TMA 的含量,对Graves病的疗效观察、预后判断及早发甲减的预后评估具有重要的意义.因此,这些实验项目对Graves病而言,应置于优先的考虑.
展开▼
